BUSINESS
Biomedix Takes Over Originator Data as Generics Face Supply, Information Challenge
Quick Look: Biomedix will inherit key product information for Rocaltrol after Chugai’s withdrawal, amid rising concern over the loss of originator LLP data. The move reflects a broader shift in generics toward supply reliability and information continuity as brand-name exits…
To read the full story
Related Article
- Chugai to Discontinue Sale of Rocaltrol in Japan
November 7, 2024
BUSINESS
- Nipro’s Stemirac Clinches Full Approval in Japan
November 17, 2026
- Kyorin Bags Japan Rights to Acadia’s Rett Syndrome Drug
November 17, 2026
- Eisai, J&J, Takeda among Firms Rolling Out Newly Listed Medicines in Japan
November 16, 2026
- Fuji Poised to Hit 10 Billion Yen Biosimilar Sales Mark, Led by Eylea Follow-On
November 16, 2026
- Seikagaku Sees Over a Year Before US Refiling of Herniated Disk Drug
November 16, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





